Anstett, K., Fusco, R., Cutillas, V., Mesplède, T., & Wainberg, M. A. (2015). Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity. J Virol.

Anstett, Kaitlin, Robert Fusco, Vincent Cutillas, Thibault Mesplède, et Mark A. Wainberg. "Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations Under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity." J Virol 2015.

Anstett, Kaitlin, et al. "Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations Under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity." J Virol 2015.